drugset / Trial / NCT05154383
Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression
Phase 4
Completed
60 enrolled
Centre Hospitalier Annecy Genevois
Euraxi Pharma · collabEurofins Optimed · collabHospices Civils de Lyon · collabInstitut National de la Santé Et de la Recherche Médicale, France · collabSanofi Pasteur, a Sanofi Company · collab
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of the study is to evaluate innate and adaptive immunity following QIV-HD vaccination compared to QIV-SD vaccination in people 65 years of age and older.
Timeline
- Start
- 2021-11-15
- Primary completion
- 2022-07-21
- Completion
- 2022-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efluelda | Vaccine | — | — |
| Comparator | Influvactetra | Vaccine | — | — |
Indications
No indication recorded.